Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Wet-Cupping's Impact on Pancreatitis Induced by Hypertriglyceridemia: A case study and brief literature review.
Sultan Qaboos Univ Med J
November 2024
Internal Medicine Residency Training Program, Oman Medical Specialty Board, Muscat, Oman.
Article Synopsis
- Familial hypertriglyceridemia is a genetic disorder that causes high levels of triglycerides in the blood, which can lead to acute and chronic pancreatitis.
- A 34-year-old male patient in Muscat, Oman, diagnosed with this condition experienced a significant reduction in triglycerides and a decrease in hospital admissions for pancreatitis after starting cupping therapy.
- This case report suggests that cupping therapy may help manage familial hypertriglyceridemia and lower the risk of pancreatitis.
A contemporary snapshot of familial hypercholesterolemia registries.
Curr Opin Lipidol
December 2024
Medical School, University of Western Australia, Perth.
Article Synopsis
- - Familial hypercholesterolemia (FH) registries collect important data on the management of FH, including real-world practices, epidemiology, and how late diagnoses affect cardiovascular health and healthcare use.
- - Most adult patients with heterozygous FH (HeFH) are diagnosed late and often do not achieve recommended cholesterol levels, while genetic testing is crucial for early detection in children and adolescents.
- - Data from these registries highlight the need for better strategies to improve FH care globally, particularly addressing disparities in treatment and outcomes based on income levels.
The singular French PCSK9-p.Ser127Arg gain-of-function variant: A significant player in cholesterol levels from a 775-year-old common ancestor.
Atherosclerosis
December 2024
Paris Cité University and Sorbonne Paris Nord University, INSERM UMRS 1148, Laboratory for Vascular Translational Science (LVTS), F-75018, Paris, France. Electronic address:
Article Synopsis
- PCSK9 is crucial for regulating LDL-cholesterol and certain variants, like p.Ser127Arg, lead to higher cholesterol levels and are mainly found in France, with few in South Africa and Norway due to a common ancestor effect.
- The study analyzed 14 p.Ser127Arg carriers from eight families and compared them with other variants to understand their genetic background and health impact.
- Results indicated that the common ancestor lived about 775 years ago, and carriers of p.Ser127Arg had significantly higher LDL-C levels, suggesting it may have a stronger effect on cholesterol levels compared to other mutations.
The effect of lipid-lowering treatment on indices of MASLD in familial hypercholesterolemia patients.
Clin Nutr
December 2024
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Medicine, Boston VA Healthcare System, Boston, MA, USA. Electronic address:
Background & Aims: The effect of lipid-lowering treatment (LLT) on metabolic dysfunction associated steatotic liver disease (MASLD) is unclear. This is relevant for patients with familial hypercholesterolemia (FH) who are on lifelong LLT. We aimed to evaluate the effect of LLT on MASLD indices in this population.
View Article and Find Full Text PDFLomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study.
Lancet Diabetes Endocrinol
December 2024
Amryt Pharmaceuticals, Dublin, Ireland.
Article Synopsis
- Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder that causes extremely high LDL cholesterol levels, leading to heart disease at an early age; lomitapide is a medication designed to lower these cholesterol levels in affected adults and is being tested for safety and efficacy in children.
- The APH-19 study involved 43 pediatric patients aged 5-17 years on existing cholesterol treatments; they received varying doses of lomitapide over a 24-week period to measure its effect on LDL cholesterol levels and other lipid parameters.
- Results indicated a significant decrease in LDL cholesterol by 53.5% after 24 weeks of treatment, suggesting lomitapide may be effective for managing cholesterol
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!